Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BIPHETAMINE 7.5 vs A/T/S
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Biphetamine 7.5 is a combination of amphetamine enantiomers (dextroamphetamine and levoamphetamine) that increase synaptic concentrations of dopamine and norepinephrine by inhibiting presynaptic reuptake and promoting release into the synaptic cleft.
A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
Attention deficit hyperactivity disorder (ADHD),Narcolepsy
Treatment of acne vulgaris (FDA-approved indication),Treatment of bacterial infections caused by susceptible organisms (off-label use for acne is the primary use)
Initial 7.5 mg orally once daily in the morning, titrated based on response and tolerability. Maximum daily dose is 30 mg.
Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.
6-8 hours (amphetamine moiety), 10-13 hours (dextroamphetamine); clinical effects may outlast serum levels due to accumulation.
Terminal elimination half-life: 1–2 hours (prolonged in hepatic impairment).
Hepatic metabolism via CYP2D6, deamination, and glucuronidation; major metabolites include 4-hydroxyamphetamine and hippuric acid.
Antithrombin is a glycoprotein; its metabolism involves cellular uptake and catabolism, but specific CYP450 enzymes are not involved. Degradation occurs via proteolysis and reticuloendothelial system clearance.
Renal: ~70-90% unchanged and as active metabolites; minor fecal elimination. Acidic urine (p H <5.6) increases excretion; alkaline urine (p H >7.0) decreases it.
Renal: 10-20% (active drug and metabolites); Fecal: minimal; Biliary: not significant.
~16-20%; primarily albumin and alpha-1-acid glycoprotein.
70-90% bound to serum albumin.
4-5 L/kg; extensive tissue distribution with high CNS penetration.
0.5–0.8 L/kg (low Vd, minimal tissue penetration).
PO: 75-100% (immediate-release); food delays absorption but does not affect total AUC.
Topical: 1–5% (minimal systemic absorption).
GFR 15-29 m L/min: 50% of normal dose; GFR <15 m L/min: avoid use.
No specific adjustment required; drug is not renally eliminated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
No specific adjustment; antithrombin is produced in the liver, but exogenous replacement does not require dose adjustment in hepatic impairment.
Children 6-17 years: initial 2.5 mg orally once daily; may increase by 2.5-5 mg weekly; maximum 30 mg daily.
Dosing based on weight and antithrombin levels; typical initial dose 30-50 IU/kg, followed by maintenance to achieve target levels. Clinical trial data limited in neonates.
Start at 2.5 mg orally once daily; increase by 2.5 mg weekly as tolerated; monitor for cardiovascular effects and insomnia.
No specific adjustment; use standard dosing with monitoring of antithrombin activity and bleeding risk.
WARNING: ABUSE AND DEPENDENCE. Amphetamines have a high potential for abuse; prolonged use may lead to drug dependence; misuse may cause sudden death or serious cardiovascular events.
None.
Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase may occur; monitor for hypertension and tachycardia.,Psychiatric adverse reactions: exacerbation of pre-existing psychosis, mania, aggression, or new psychotic/manic symptoms.,Long-term suppression of growth in children; monitor height and weight.,Seizures: may lower seizure threshold; discontinue if seizures occur.,Peripheral vasculopathy: Raynaud's phenomenon; monitor for digital changes.
Hypersensitivity reactions including anaphylaxis have occurred.,Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Use with caution in patients with hepatic impairment.,Potential for QT prolongation and ventricular arrhythmias, especially with intravenous administration or concomitant drugs that prolong QT interval.
Hypersensitivity to amphetamine or other sympathomimetic amines,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation,Glaucoma,Hyperthyroidism,Moderate to severe hypertension,Advanced arteriosclerosis,Symptomatic cardiovascular disease,History of drug abuse
Hypersensitivity to erythromycin or any macrolide antibiotic.,Use with caution in patients with pre-existing QT prolongation or electrolyte abnormalities (relative contraindication).
Avoid high-fat meals as they may delay absorption. Avoid excessive caffeine intake as it may potentiate stimulant effects and increase anxiety. Ensure adequate hydration to reduce the risk of dry mouth and constipation. No specific foods are contraindicated, but a balanced diet is recommended to mitigate appetite suppression.
No specific food interactions. Avoid excessive alcohol consumption as it may increase skin dryness.
Pregnancy category C. First trimester: possible increased risk of congenital malformations (e.g., cardiac, orofacial clefts) based on limited human data and animal studies. Second and third trimesters: risk of fetal growth restriction, preterm delivery, and neonatal withdrawal symptoms (including irritability, hyperexcitability). Use only if potential benefit justifies risk.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk to fetus is low across all trimesters.
Not recommended. Amphetamine is excreted into breast milk; M/P ratio not established. Potential for infant exposure causing adverse effects such as irritability, poor feeding, and sleep disturbance. American Academy of Pediatrics recommends contraindication.
Compatible with breastfeeding. Erythromycin is excreted into breast milk in small amounts (M/P ratio approximately 0.5). Topical use results in negligible systemic exposure; unlikely to cause adverse effects in nursing infants.
No established dosing guidelines. Pregnancy may alter pharmacokinetics of amphetamines due to increased plasma volume and hepatic metabolism; consider using the lowest effective dose. Monitor clinical response and adjust as needed.
No dose adjustment required. Systemic absorption from topical application is minimal and not significantly altered by pregnancy-related pharmacokinetic changes.
Biphetamine 7.5 is a fixed-dose combination of amphetamine and dextroamphetamine (ratio 1:1) used for ADHD. Monitor for cardiovascular adverse effects including hypertension, tachycardia, and sudden cardiac death, especially in patients with structural cardiac abnormalities. Avoid in patients with a history of drug abuse due to high abuse potential. Use with caution in patients with bipolar disorder as it may induce manic episodes. Assess for growth suppression in pediatric patients during long-term therapy.
A/T/S (erythromycin 2% topical solution) is indicated for acne vulgaris. Avoid contact with eyes, mouth, and mucous membranes. May cause skin dryness or irritation; use moisturizer. Effectiveness may decrease with prolonged use due to bacterial resistance. Not recommended for use with other topical erythromycin products or clindamycin to avoid antagonism.
Take the medication exactly as prescribed; do not increase the dose or frequency without consulting your doctor.,Avoid taking this medication late in the day to prevent sleep disturbances.,Report any chest pain, shortness of breath, or fainting immediately.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,Store in a secure location away from children and others to prevent misuse.,Attend regular follow-ups for blood pressure, heart rate, and growth monitoring (in children).
Apply a thin layer to affected areas twice daily after washing.,Avoid contact with eyes, lips, and mouth; if contact occurs, rinse thoroughly with water.,May cause stinging, burning, or peeling; if irritation persists, consult your doctor.,Use sunscreen daily as this medication may increase sensitivity to sunlight.,Do not use more than prescribed; overuse may increase side effects without improving results.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep away from open flames or heat sources; product is flammable.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BIPHETAMINE 7.5 vs A/T/S, answered by our medical review team.
BIPHETAMINE 7.5 is a Central Nervous System Stimulant that works by Biphetamine 7.5 is a combination of amphetamine enantiomers (dextroamphetamine and levoamphetamine) that increase synaptic concentrations of dopamine and norepinephrine by inhibiting presynaptic reuptake and promoting release into the synaptic cleft.. A/T/S is a Macrolide antibiotic that works by A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BIPHETAMINE 7.5 and A/T/S depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BIPHETAMINE 7.5 is: Initial 7.5 mg orally once daily in the morning, titrated based on response and tolerability. Maximum daily dose is 30 mg.. The standard adult dose of A/T/S is: Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BIPHETAMINE 7.5 and A/T/S in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BIPHETAMINE 7.5 is classified as Category C. Pregnancy category C. First trimester: possible increased risk of congenital malformations (e.g., cardiac, orofacial clefts) based on limited human data and animal studies. Second . A/T/S is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.